Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003923 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
A Phase 2 study of Pancreatic Cancer and Liver Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT00003923: Completed Phase 2 study of Pancreatic Cancer and Liver Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003923 is a Phase 2 study of Pancreatic Cancer and Liver Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003923, a Phase 2 study of Pancreatic Cancer and Liver Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas. PURPOSE: Phase II trial to determine the effectiveness of photodynamic therapy in treating patients who have cancer of the bile duct, gallbladder, or pancreas.
Conditions Studied
Interventions
- DRUG porfimer sodium
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 1999-03 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
What the finished NCT00003923 record still lists
NCT00003923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which porfimer sodium is the first listed.
NCT00003923 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00003923 about?
NCT00003923 is a clinical study titled "Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas". RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas. PURPOSE: Phase II trial to determine the effectiveness of photodynamic therapy in treating ...
What is the current status of trial NCT00003923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 1999-03. Estimated completion is 2002-02.
What conditions does trial NCT00003923 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Liver Cancer, Gallbladder Cancer, Extrahepatic Bile Duct Cancer.
What interventions are being tested in trial NCT00003923?
The interventions under investigation include: porfimer sodium (DRUG).
Who is sponsoring clinical trial NCT00003923?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003923 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003923's enrollment target sits among peer trials
4 276th of 278 higher than 2 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia